Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Sold by Rosalind Advisors Inc.

Rosalind Advisors Inc. lessened its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 1.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,805,390 shares of the biopharmaceutical company’s stock after selling 26,610 shares during the period. Abeona Therapeutics accounts for about 5.0% of Rosalind Advisors Inc.’s portfolio, making the stock its 6th largest position. Rosalind Advisors Inc. owned approximately 4.15% of Abeona Therapeutics worth $10,056,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Western Standard LLC boosted its holdings in Abeona Therapeutics by 7.0% in the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after acquiring an additional 110,998 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Abeona Therapeutics by 21.7% during the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock valued at $2,942,000 after acquiring an additional 83,050 shares in the last quarter. Citigroup Inc. raised its position in shares of Abeona Therapeutics by 10.1% during the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after purchasing an additional 56,332 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Abeona Therapeutics by 74.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after purchasing an additional 28,606 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Abeona Therapeutics in the 3rd quarter valued at $160,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, February 19th. StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 22nd. Finally, Oppenheimer began coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price target for the company. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Abeona Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.50.

Abeona Therapeutics Stock Up 0.2 %

ABEO opened at $5.15 on Friday. Abeona Therapeutics Inc has a fifty-two week low of $3.05 and a fifty-two week high of $8.45. The firm has a market capitalization of $223.88 million, a P/E ratio of -1.91 and a beta of 1.79. The company’s 50-day moving average is $5.44 and its 200 day moving average is $5.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.19. Research analysts expect that Abeona Therapeutics Inc will post -1.16 earnings per share for the current fiscal year.

Abeona Therapeutics Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.